Sanofi and Institut Pasteur create awards to support biomedical research

Will split €480,000 among four winners

French pharmaceutical firm Sanofi and the Institut Pasteur, an internationally renowned centre of biomedical research, have created the Sanofi-Institut Pasteur Awards to encourage scientific excellence in the service of health.

The Sanofi-Institut Pasteur Awards will give a total of €480,000 to four innovative research projects in the areas of neglected tropical diseases, vaccine innovation, drug resistance, and therapeutic approaches to ageing and regenerative medicine, which demonstrate real progress in the life sciences and provide answers to these major healthcare problems. Each award winner will receive €120,000, split €40,000 for the researcher and €80,000 to support the research.

The judging panel is composed of: Peter Agre, Johns Hopkins University, Baltimore, US, Nobel Prize in Chemistry 2003; Elizabeth Blackburn, University of California, San Francisco, Nobel Prize in Medicine 2009; Pascale Cossart, head of the Bacteria-Cell Interactions Unit, Institut Pasteur; Alice Dautry, president of the Institut Pasteur; Depei Liu, vice president of the Academy of Engineering of China and president of the Chinese Academy of Medical Sciences and the Peking Union Medical College; Robert Sebbag, vice president, Access to Medicines at Sanofi; and Elias Zerhouni, president, Global R&D at Sanofi.

‘With these awards, the Institut Pasteur confirms its commitment to the greater interest by encouraging research, notably in conditions affecting the most vulnerable populations and diseases sharply on the rise in the world,’ said Dautry.

Candidates should submit their applications by 20 April. The prizes will be awarded in November at the Institut Pasteur in Paris, France.

You may also like

Research & Development

Sanofi and Orano Med join forces to develop next-gen oncology medicines

The companies will combine their biotech and R&D expertise to develop rare cancer-targeting radioligand therapies (RLTs)
Research & Development

Sanofi's tolebrutinib meets primary endpoints in Phase III HERCULES MS trial

The therapeutic has the ability to delay the onset of confirmed disability progression in patients, which is significant area of unmet need in the MS patient population
Manufacturing

Sanofi and Novavax co-commercialise COVID-19 vaccine

The agreement will aim to commercialise Novavax's adjuvanted COVID-19 vaccination globally, as well as develop a COVID-19 and flu combination vaccine
Research & Development

LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint

Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Research & Development

Sanofi and Teva's collaboration to deliver inflammatory bowel disease treatment

TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease by Sanofi and Teva Pharmaceuticals
Ingredients

Therapeutic: efanesoctocog alfa for haemophilia A

Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Research & Development

C4XD receives first milestone payment of €3 million from Sanofi

€3 million milestone payment triggered by preclinical progression in oral IL-17A inhibitor programme
Subscribe now